WHO Country Office, Nepal.
Family Welfare Division, Department of Health Services, Ministry of Health and Population, Nepal.
Vaccine. 2020 Sep 11;38(40):6320-6326. doi: 10.1016/j.vaccine.2020.07.035. Epub 2020 Aug 9.
Surveillance for adverse events following immunization (AEFI) is important to monitor vaccine safety and should lead to appropriate responses to improve health and immunization program. Bleeding following vaccination is not recognized as an important AEFI. Without policy of vitamin K (VK) prophylaxis at birth, vitamin K deficiency bleeding (VKDB) could be an important cause of bleeding in young infants and may manifest as AEFI.
We retrospectively analysed all serious AEFI cases that presented with external or internal bleeding reported to Nepal's AEFI surveillance system during 2016-2018. The cases were classified as VKDB, suspected VKDB or non-VKDB.
During the period, 16 serious AEFI with symptom or sign of bleeding were reported representing 21.3% of all serious AEFI reported. Cases were between 40 and 94 days of age. The National AEFI Investigation Committee classified all cases as coincidental. Fourteen cases (87.5%) had bleeding from injection site. Median time from vaccination to injection site bleeding was 4.3 h (interquartile range: 2.1-11.6 h). Six cases (37.5%) had intra-cranial haemorrhage. Only one case had confirmed history of receiving VK at birth. Ten cases (62.5%) received appropriate treatment (VK injection; blood transfusion if needed). Based on limited laboratory investigations available, three cases (18.75%) could be classified as late onset VKDB and 11 cases (68.75%) as suspected late onset VKDB.
VKDB should be suspected in young infants presenting with bleeding including following vaccination, and prompt treatment should be initiated. Bleeding following vaccination should be recognized as an important AEFI as even a small amount of blood loss in young infants can be catastrophic. We posit that this series is a small subset of VKDB cases in Nepal detected through AEFI surveillance system. In countries without policy of VK prophylaxis at birth including Nepal, the policy should be introduced.
疫苗接种后不良反应(AEFI)监测对于监测疫苗安全性非常重要,应采取适当措施以改善健康和免疫规划。接种后出血并不被认为是一种重要的 AEFI。如果没有出生时维生素 K(VK)预防政策,VK 缺乏性出血症(VKDB)可能是婴儿出血的一个重要原因,并可能表现为 AEFI。
我们回顾性分析了 2016 年至 2018 年期间尼泊尔 AEFI 监测系统报告的所有有外部或内部出血症状或体征的严重 AEFI 病例。这些病例被分为 VKDB、疑似 VKDB 或非 VKDB。
在此期间,报告了 16 例有症状或体征的严重 AEFI 出血病例,占报告的所有严重 AEFI 的 21.3%。病例年龄在 40 至 94 天之间。国家 AEFI 调查委员会将所有病例均归类为偶合症。14 例(87.5%)有注射部位出血。从接种到注射部位出血的中位时间为 4.3 小时(四分位间距:2.1-11.6 小时)。6 例(37.5%)有颅内出血。只有 1 例有明确的出生时接受 VK 的病史。10 例(62.5%)接受了适当的治疗(VK 注射;如有必要输血)。根据现有的有限实验室检查结果,3 例(18.75%)可归类为迟发性 VKDB,11 例(68.75%)为疑似迟发性 VKDB。
对于出现出血(包括接种后)的婴儿,应怀疑 VKDB,并应立即开始治疗。接种后出血应被视为一种重要的 AEFI,因为即使是婴儿的少量失血也可能是灾难性的。我们认为,通过 AEFI 监测系统发现的本系列病例只是尼泊尔 VKDB 病例的一小部分。在没有出生时 VK 预防政策的国家,包括尼泊尔,应引入该政策。